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Background: The amount of epicardial adipose tissue (EAT) around the heart has been identified as an
independent predictor of coronary artery disease (CAD), potentially through local release of inflammatory cytokines.
Ethnic differences have been observed, but no studies have investigated this relationship in the Mexican
population. The objective of the present study was to evaluate whether a relationship exist between EAT thickness
assessed via echocardiography with CAD and adiponectin levels in a Mexican population.
Methods: We studied 153 consecutive patients who underwent coronary angiography and transthoracic
echocardiography (TTE). EAT thickness on the free wall of the right ventricle was measured at the end of systole
from parasternal long and short axis views of three consecutive cardiac cycles. Coronary angiograms were analyzed
for the presence, extent and severity of CAD. Serum adiponectin, lipids, glucose, C-reactive protein and fibrinogen
were determined.
Results: EAT thickness was greater in patients with CAD than in those without CAD from both parasternal long
(5.39 ± 1.75 mm vs 4.00 ± 1.67 mm p < 0.0001) and short-axis views (5.23 ± 1.67 vs 4.12 ± 1.77, p = 0.001). EAT
thickness measured from parasternal long and short-axis showed a statistically significant positive correlation with
age (r = 0.354, p < 0.001; r = 0.286, p < 0.001 respectively), and waist circumference (r = 0.189, p = 0.019; r = 0.217,
p = 0.007 respectively). A significant negative correlation between EAT thickness from the parasternal long axis with
cholesterol-HDL was observed (r = −0.163, p = 0.045). No significant correlation was found between epicardial fat
thickness and serum adiponectin or with the severity of CAD.
Conclusions: EAT thickness was greater in patients with CAD. However, no correlation was observed with the
severity of the disease or with serum adiponectin levels. EAT thickness measured by echocardiography might
provide additional information for risk assessment and prediction of CAD.
Keywords: Epicardial adipose tissue, Coronary artery disease, Echocardiography, AdiponectinBackground
Obesity is the most prevalent risk factor for coronary ar-
tery disease [1]. Regional body adipose tissue distribu-
tion, rather than total body adiposity, is a known marker
for cardiovascular risk [2]. A variety of pro and anti-
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article, unless otherwise stated.adipose tissue and have been demonstrated to partici-
pate in the various stages of atherogenesis [3]. Adiponec-
tin is exclusively identified in mature adipocytes and
decreased plasma levels are associated with atheroscler-
osis [4]; adiponectin levels are inversely correlated with
the amount of visceral adipose tissue and may serve as a
predictive factor for cardiovascular risk [5,6]. Epicardial
adipose tissue (EAT) locally expresses adiponectin pro-
tein, with significantly lower levels in patients with cor-
onary artery disease (CAD) [7-9].ntral Ltd. This is an Open Access article distributed under the terms of the
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heart, particularly around epicardial coronary vessels. Be-
cause of its proximity to the myocardium and absence of
fascia, epicardial fat may directly affect the coronary arter-
ies and myocardium through paracrine actions of locally
secreted adipocytokines and other bioactive molecules,
contributing to the development of CAD [7,10,11].
Recently, a meta-analysis demonstrated that EAT thick-
ness is an effective marker for predicting CAD [12]. How-
ever, several studies have shown that race can affect the
distribution of intra-abdominal adipose tissues [13], and
also participate in the observed differences in EAT thick-
ness [14,15]. Mexico exhibits the highest obesity prevalence
in the world, even so, to our knowledge there are no pub-
lished studies on EAT thickness related to CAD and adipo-
nectin. Thus, the present study was designed to assess
whether an association exists between epicardial adipose
tissue measured by transthoracic echocardiography with
CAD and serum adiponectin in a Mexican population.
Methods
Patients
From February 2011 to June 2013, we conducted a cross-
sectional study on all patients admitted for elective coron-
ary angiography for suspected coronary artery disease.
For all subjects, clinical data and anthropometric mea-
sures were recorded. Individuals were considered as type
2 diabetic if they had been previously diagnosed, were
receiving hypoglycemic treatment and/or insulin, or had a
fasting glucose level of >126 mg/dl on two or more
occasions. Hypertension was defined as systolic blood
pressure ≥140 mmHg, diastolic blood pressure >90
mmHg or if previously diagnosed or receiving a previ-
ously established antihypertensive therapy. Hyperlipid-
emia was defined as a total cholesterol (TC) ≥200 mg/
dl, Low-density lipoprotein cholesterol (LDL-choles-
terol) greater than ≥160 mg/dl, triglycerides (TG) ≥150
mg/dl and/or a previous diagnosis or treatment. De-
creased levels of high-density lipoprotein cholesterol
(HDL-C) were defined as <40 mg/dl. Patients were con-
sidered smokers if they had smoked five or more ciga-
rettes a day and had suspended this habit for longer
than one year. Body mass index (BMI) was calculated by a
standard formula [weight (kg)/height (m)2]. Central obes-
ity was considered if the waist circumference was ≥90 cm
in men and ≥80 cm in women [16]. Patients with more
than three of five criteria based on the International Dia-
betes Federation (IDF) were considered to have metabolic
syndrome (MS). Patients were excluded if they had any
of the following: chronic renal and/or hepatic disease,
history of prior revascularization, patients with pericar-
dial effusion and whose transthoracic echocardiographic
imaging was inadequate for the measurement of epicar-
dial fat thickness. Mexican Social Security Institute(IMSS) Research Committee approved the study proto-
col, and all patients gave written informed consent.
Laboratory measurements
Blood samples were obtained after a fast of at least 8 h.
Serum and plasma were immediately distributed in ali-
quots and frozen at −70°C for less than six months. The
samples were analyzed in blocks to reduce inter-assay
variability. Glucose concentrations, plasma lipid profile
and high sensitivity C-reactive protein (hsCRP) were mea-
sured using the Architect Clinical Chemistry Autoanalyzer
System from Abbott Clinical Chemistry (Chicago, IL,
USA). The assay reliability of these parameters was < 5%
coefficient of variation. Fibrinogen determination was per-
formed using ACL Elite Pro equipment with the Clauss
method. Plasma concentrations of adiponectin were deter-
mined using a commercially available immunoassay kit
SPI-bio Bertin Pharma (Montigny le Bretonneux, France)
and the values were expressed in μg/ml.
Evaluation of epicardial adipose tissue
Two-dimensional transthoracic echocardiography (Philips
iE33, with 3.5 MHz transducer) in the left lateral decubitus
position was performed. Measurements were performed
by a cardiologist who was unaware of angiographic data.
Epicardial adipose tissue was identified as echo-free space
in the pericardial layers on the two-dimensional echocar-
diography and its thickness was measured perpendicularly
on the free wall of the right ventricle at the end of systole,
repeated over three cardiac cycles. Two standard echocar-
diographic windows, parasternal long-axis and short-axis,
were used. A pre-specified anatomical reference for each
echocardiographic window was considered as a standard
measurement point in order to be consistent with other
studies. For the parasternal long axis view, the anatomical
reference was the aortic annulus. Measurements were per-
formed at the point on the right ventricular free wall in
the midline with the ultrasound beam, perpendicular to
the aortic annulus. For the parasternal short axis view, epi-
cardial adipose tissue thickness was measured on the right
ventricular free wall, 2 cm from the ventricular septum.
We calculated an average value of three cardiac cycles for
each echocardiographic window for statistical analysis.
Echocardiographic measurement of epicardial thickness
was defined as an epicardial thickness >1 mm in at least
one acoustic window. The reliability of transthoracic echo-
cardiography for measuring EAT thickness, has been con-
firmed by its good correlation with magnetic resonance
imaging [17].
Coronary artery occlusion assessment
Selective coronary angiography was performed using
femoral access in all patients. Patients were classified as
CAD+, defined as >50% stenosis in at least one major
Table 1 Clinical and laboratory characteristics in patients
with and without coronary artery disease
CAD- (n = 34) CAD + (n = 119) p value
Age (years) 59.18 ± 12.25 61.76 ± 10.05 0.210
Male gender,
n (%)
14 (41.1) 98 (82.3) <0.001
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http://www.cardiovascularultrasound.com/content/12/1/35coronary artery, or CAD −with no angiographic evidence
of significant coronary artery occlusion. Severity of coron-
ary atherosclerosis was classified as 1-, 2-, or 3-vessel dis-
ease according to the number of stenotic major coronary
arteries (left anterior descending artery, circumflex artery
and right coronary artery).BMI (kg/m2) 30.74 ± 5.90 28.92 ± 3.87 0.198
Central obesity
n (%)
33 (97.0%) 118 (99.1%) 0.791
WC (cm) 100.97 ± 11.81 103.47 ± 8.81 0.256
Waist-hip ratio 0.92 ± 0.08 0.98 ± 0.06 <0.001
Smoking, n (%) 6 (17.6) 64 (53.7) <0.001
Diabetes mellitus,
n (%)
13 (38.2) 65 (54.6) 0.093
Hypertension,
n (%)
26 (76.5) 85 (71.4) 0.564
Hyperlipidemia,
n (%)
24 (70.5) 85 (71.4) 0.924
Metabolic
syndrome n (%)
29 (85.2) 111 (93.2) 0.141
FPG (mg/dl) 104.0 (95.00-119.25) 119.5 (97.00-152.25) 0.076
Total cholesterol
(mg/dl)
175.97 ± 41 164.94 ± 48.55 0.231
LDL-C (mg/dl) 103.85 ± 33.58 91.63 ± 37.33 0.088
HDL-C (mg/dl) 42.35 ± 11.35 35.81 ± 8.94 0.003
TG (mg/dl) 141 (106.5-203.5) 151 (105.0-245.0) 0.353
hsCRP (mg/dl) 1.08 ± 2.08 3.01 ± 5.65 0.002
Adiponectin
(μg/ml)
11.66 ± 6.77 8.88 ± 4.64 0.039
Fibrinogen
(mg/dl)
547.0 (469.0-660.0) 591.5 (480.5-744.0) 0.090
Data are expressed as number and % of patients, mean ± SD or median (25th,
75th percentiles). CAD – Coronary artery disease; BMI – Body mass index;
WC – Waist circumference; FPG – fasting plasma glucose; LDL-C – low-density
lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; TG –
triglycerides; hsCRP – high sensitivity C-reactive protein. Central obesity was
defined as increased waist circumference.Statistical analysis
We used descriptive statistics with mean ± SD or median
with interquartile range values in accordance with their
distribution. Student’s t-test or Mann–Whitney tests were
performed to compare the differences between continuous
variables according to their distribution. Significant differ-
ences between categorical variables were evaluated using a
Chi-square test. The Pearson or Spearman correlation
tests were used to evaluate an association of EAT and adi-
ponectin with other quantitative variables. Multiple logis-
tic regression analysis was used to estimate the association
between variables and the presence or absence of CAD. In
order to determine the predictive value of EAT thickness
and adiponectin levels multiple logistic regression analysis
was applied to these variables as well as the other factors
including conventional clinical variables. In this model,
those variables that showed p values < 0.05 in the univari-
ate analysis were included. Odds ratios and 95% confi-
dence intervals (CIs) for CAD+ vs CAD- were calculated.
A value of p < 0.05 was considered to be statistically sig-
nificant. Analyses were performed using SPSS, version 15
(Chicago, IL, USA).
To assess the reproducibility of echocardiographic mea-
surements of epicardial adipose tissue, 24 patients were
randomly selected for off-line analysis by two observers
who were unaware of clinical and angiographic data and
inter-observer correlation coefficients were calculated. In
the same group of patients, echocardiographic measure-
ments were repeated two days later to calculate intra-
observer correlation coefficients.Results
Clinical characteristics
Clinical and laboratory data of 153 patients with or
without CAD are summarized in Table 1. Our patient
cohort consisted of 119 subjects with CAD (77.7%) and
34 subjects without CAD (22.2%). Male gender was
more predominant in the CAD + group (p < 0.001).
Compared to those without significant stenosis, patients
with CAD had higher waist-hip ratio (0.98 ± 0.06 vs
0.917 ± 0.08, p < 0.001), showed a higher C-reactive pro-
tein (3.01 ± 5.65 vs.1.08 ± 2.08 mg/dl, p = 0.002) and a
lower HDL cholesterol level (42.35 ± 11.35 vs. 35.81 ±
8.94 mg/dl, p = 0.003). The ejection fraction measured
by echocardiography was similar between the CAD- and
CAD + groups.EAT thickness and coronary artery disease
Inter-observer and intra-observer correlation coeffi-
cients of EAT thickness measurements were 0.96 and
0.94 respectively, indicating excellent reproducibility of
echocardiographic measurements. Mean values of epi-
cardial adipose tissue thickness from the parasternal
long and short axes views in all patients were 5.08 ± 1.82
and 4.99 ± 1.75 mm, respectively. Forty-eight (31.4%)
patients had single vessel, 36 (23.5%) two vessels and 35
(22.9%) had three vessels with >50% of stenosis. Table 2
shows the echocardiographic data. EAT was thicker in
patients with CAD than in those without CAD in both
the parasternal long axis (5.39 ± 1.75 vs 4.00 ± 1.67 mm,
p < 0.0001) and short axis (5.23 ± 1.67 vs 4.12 ± 1.77 mm,
p = 0.001) views.
Table 2 Echocardiographic findings in patients with and
without coronary artery disease
CAD- (n = 34) CAD + (n = 119) p value
EAT PLX (mm) 4.00 ± 1.67 5.39 ± 1.75 <0.0001
EAT PSX (mm) 4.12 ± 1.77 5.23 ± 1.67 0.001
EAT – epicardial adipose tissue; PLX – parasternal long-axis view, PSX –
parasternal short-axis view.
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clinical, biochemical and angiographic variables
Table 3 shows the correlations of EAT with clinical,
biochemical and angiographic variables. EAT thickness
measured from the long and short axes showed a signifi-
cant positive correlation with age (r = 0.354, p < 0.001
and r = 0.286, p < 0.001 respectively); with waist circum-
ference (r = 0.214, p = 0.008 and r = 0.234, p = 0.004);
with waist-hip ratio (r = 0.189, p = 0.019 and r = 0.217,
p = 0.007); with waist-height ratio (r = 0.243, p = 0.002
and r = 0.267, p = 0.001). EAT thickness was inversely cor-
related with the level of high-density lipoprotein choles-
terol (r = −0.163, p = 0.045). Eighty-five percent of subjects
in the CAD- group and 92% in the CAD+ group had MS
(Table 1). No significant differences were observed in EAT
thickness between patients with MS and without MS in
the parasternal long axis (5.05 ± 1.83 vs 5.38 ± 1.74 mm,
p = 0.539) and parasternal short axes (4.99 ± 1.75 vs
4.97 ± 1.82 mm, p = 0.970), respectively. There was no sig-
nificant correlation between echocardiographic epicardialTable 3 Univariate correlations between cardiac adipose
tissue thickness and clinical variables
EAT PLX p value EAT PSX p value
r r
Age 0.354 <0.001 0.286 <0.001
Height −0.004 0.958 0.000 0.997
Weight −0.023 0.780 −0.004 0.963
Body surface area −0.009 0.911 −0.003 0.972
BMI 0.049 0.552 0.070 0.389
Waist 0.214 0.008 0.234 0.004
Hip 0.097 0.231 0.107 0.187
WHR 0.189 0.019 0.217 0.007
WHeR 0.243 0.002 0.267 0.001
Total cholesterol −0.008 0.919 −0.057 0.481
HDL-C −0.163 0.045 −0.139 0.087
LDL-C −0.032 0.637 0.096 0.245
Glucose 0.118 0.148 0.060 0.462
hsCRP 0.125 0.124 0.110 0.176
Fibrinogen 0.132 0.107 0.137 0.094
Adiponectin −0.092 0.257 −0.073 0.368
Number of stenotic vessels 0.004 0.963 0.028 0.763adipose tissue thicknesses and the number of stenotic
vessels.
Relationship between adiponectin, CAD and epicardial
adipose tissue
Serum adiponectin levels were significantly lower in pa-
tients with CAD (11.66 ± 6.77 vs 8.88 ± 4.64 μg/ml, p =
0.039). However, no significant correlations were found
between EAT thickness obtained from the long- or
short-axes and serum adiponectin (Table 3). Moreover,
adiponectin levels in this sample were not a predictor of
CAD (Table 4).
Epicardial adipose tissue as a predictor of coronary artery
disease
Table 4 shows the results of the multivariate logistic re-
gression analysis. Those variables that showed significant
differences in the univariate analysis were selected for
the multivariate analysis for the prediction of CAD. EAT
thickness was found to be an independent predictor of
obstructive CAD in addition to the well-known CAD
risk factors such as male gender, C-reactive protein and
low HDL cholesterol.
Discussion
This study indicates that in a Mexican population, EAT
thickness is associated with CAD. Multiple logistic ana-
lyses of several CAD risk factors suggested that EAT is
an independent factor associated with CAD. This finding
is consistent with others reports in different populations.
Ahn et al. [18], reported this relationship in a subset of
Korean patients. A recent meta-analysis showed that EAT
may be an effective marker for the prediction of coronary
heart disease [12]. In our study, mean EAT thickness in
patients with coronary heart disease was 5.2 mm, similar
to values reported by Mustelier et al. [19], in another His-
panic population. This value is lower than others found in
Japanese and USA populations [20,21], but higher than in
the Korean population [18].Table 4 Multiple logistic regression analysis for the
prediction of significant coronary artery disease
OR (95% CI) p value
Male 14.182 (3.877-51.876) <0.0001
WHR 0.952 (0.921-0.985) 0.004
Smoking 3.385 (1.064-10.767) 0.039
HDL-C 0.992 (0.943-1.044) 0.761
hsCRP 1.165 (0.979-1.385) 0.085
Adiponectin 0.977 (0.898-1.063) 0.583
EAT thickness 1.903 (1.366-2.653) <0.0001
WHR – waist-hip ratio; HDL-C – high-density lipoprotein cholesterol; hsCRP –
high sensitivity C-reactive protein; EAT – epicardial adipose tissue.
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group. Several studies have shown that ethnicity affects
the distribution of visceral adipose tissue. Willens et al.
[14], showed that non-Hispanic white males have larger
epicardial fat thickness than African-American men, in-
dependently of age, weight, and BMI. These differences
might be attributed to inherited and nongenetic factors.
However, the identities of genes that underlie population
variation in adipose tissue development in humans are
poorly understood.
The prevalence of obesity has increased worldwide, in-
cluding in Mexico. Data from the national health and
nutrition survey conducted in 2012 showed that obesity
affects 7 in 10 Mexican adults [22]. This condition is a
prominent risk factor for the development of chronic
diseases, such as CAD. Obesity has a strong genetic con-
tribution, in addition to already known environmental
and nutritional factors. Our results showed that EAT
thickness was significantly correlated with abdominal
circumference, but not with BMI. Previous authors have
shown similar findings [21]. A partial explanation is that
BMI may not predict total adiposity. Although it is known
that there are differences in the fat distribution between
males and females, in this study a gender analysis was not
possible because there were a limited number of women
included in the CAD group.
In the present study, no relationship was observed be-
tween EAT thickness and the extent of CAD. This result
agrees with previous findings from Mustelier et al. [19],
but is in contrast with others [18,23]. The lack of associ-
ation in this study could be partially attributed to the
fact that EAT measurements are not performed at a
specific anatomical site where the coronary stenosis is
located. Moreover, a larger sample size could be needed
in order to find this relationship. In this line, the extent
of CAD could be related with other risk factors or with
the existence of other metabolic disturbances.
Mechanisms that promote the development of CAD
through epicardial fat are not completely clear. The role
of epicardial fat as a metabolically active organ with para-
crine or endocrine functions is the most accepted. Previ-
ous studies have shown that adipose tissue, particularly
visceral fat, express numerous genes related to adipokine
production, which have important roles in the develop-
ment of atherosclerosis in obese patients [7,24]. Epicardial
fat located near to the coronary tree could facilitate the
paracrine effects of epicardial adipokines, as part of the
pathogenesis of CAD [11,25].
Few studies have evaluated the relationship between
EAT thickness and serum adiponectin levels. Yun et al.
[26], found a significant inverse relationship between EAT
thickness and plasma adiponectin levels in patients with
angina. Our data show that patients with CAD have sig-
nificantly lower adiponectin levels compared to non-CADsubjects, but a significant correlation between EAT thick-
ness and adiponectin was not observed. Furthermore,
multivariate analyses did not show adiponectin as an inde-
pendent variable for CAD risk.
While some studies have related epicardial fat with the
presence of inflammatory markers, a direct relationship
between these and EAT thickness or CAD has not been
demonstrated. Iacobellis et al. [12], reported that protein
expression of adiponectin from EAT in patients with ex-
tensive CAD was significantly lower than non-CAD
subjects; however, if the local adiponectin is produced
in EAT rather than systemic influences on coronary
heart disease is still debatable [27,28]. Further studies
are needed in order to clarify the relation of adiponectin
with coronary atherosclerosis.
Imaging studies demonstrated good accuracy for the
quantification of adipose tissue in various body compart-
ments, with a good correlation [15]. Transthoracic echo-
cardiography provides a reliable measurement of epicardial
adipose tissue thickness. This method has been validated
with magnetic resonance imaging [17], which is currently
the gold standard method and a widely accepted reference
standard to measure visceral adiposity.
Echocardiography as a non-invasive method that is
low in cost and widely available could be routinely per-
formed in high-risk patients for the evaluation of epicar-
dial adipose tissue and predicting CAD.
To the best of our knowledge, this is the first study to
evaluate an association between EAT thickness, CAD
and adiponectin in a Mexican population. Future studies
are required to determine reference ranges and cut-off
points for EAT thickness measured by echocardiography
in Mexican population.
Study limitations
The present study has several limitations. 1. This cross-
sectional study cannot determine causal relationships
between studied variables 2. The sample size is modest
for association studies. In the studied population, most
patients who underwent coronary catheterization have a
high risk for CAD, but only a few patients had normal
coronary arteries, so we had an unbalanced sample. How-
ever, coronary angiography is an invasive study with risks
of complications, only indicated in patients with suspected
ischemic heart disease and it would not have been ethical
to perform it in healthy patients.
Conclusions
In this study, we observed an association of epicardial
fat thickness measured by echocardiography with ath-
erosclerotic CAD, but not with the degree of severity of
the disease, or with serum levels of adiponectin. Echocar-
diography may provide additional information for predict-
ing the risk of CAD in Mexican population.
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